Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Dodick

Showing results (231-240 of 365) with videos related to

Pageof 37
Sort By:
Headache|December 16, 2020
Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment StudyRichard B Lipton, Dawn C Buse, David W Dodick, et al.
Headache|March 21, 2023
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial dataDavid Kudrow, Rima Dafer, David W Dodick, et al.
The Journal of Headache and Pain|May 21, 2024
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trialRichard B Lipton, Stephanie J Nahas, Patricia Pozo-Rosich, et al.
The Journal of Headache and Pain|March 4, 2020
Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) studyDawn C Buse, Michael L Reed, Kristina M Fanning, et al.
Headache|May 22, 2010
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programDavid W Dodick, Catherine C Turkel, Ronald E DeGryse, et al.
Annals of Neurology|April 8, 2010
Triptan-induced latent sensitization: a possible basis for medication overuse headacheMilena De Felice, Michael H Ossipov, Ruizhong Wang, et al.
Neuromodulation : Journal of the International Neuromodulation Society|August 14, 2012
Long-term outcome in occipital nerve stimulation patients with medically intractable primary headache disordersAnn Chang Brewer, Terrence L Trentman, Michael G Ivancic, et al.
Headache|August 28, 2020
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% ResponseGregor Broessner, Uwe Reuter, Jo H Bonner, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialHong Sun, David W Dodick, Stephen Silberstein, et al.
The Journal of Pain|December 3, 2014
Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an exampleDavid W Dodick, Catherine C Turkel, Ronald E DeGryse, et al.
Pageof 37

Showing results (231-240 of 365) with videos related to

Sort By:
Pageof 37
Headache|December 16, 2020
Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment StudyRichard B Lipton, Dawn C Buse, David W Dodick, et al.
Headache|March 21, 2023
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial dataDavid Kudrow, Rima Dafer, David W Dodick, et al.
The Journal of Headache and Pain|May 21, 2024
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trialRichard B Lipton, Stephanie J Nahas, Patricia Pozo-Rosich, et al.
The Journal of Headache and Pain|March 4, 2020
Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) studyDawn C Buse, Michael L Reed, Kristina M Fanning, et al.
Headache|May 22, 2010
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programDavid W Dodick, Catherine C Turkel, Ronald E DeGryse, et al.
Annals of Neurology|April 8, 2010
Triptan-induced latent sensitization: a possible basis for medication overuse headacheMilena De Felice, Michael H Ossipov, Ruizhong Wang, et al.
Neuromodulation : Journal of the International Neuromodulation Society|August 14, 2012
Long-term outcome in occipital nerve stimulation patients with medically intractable primary headache disordersAnn Chang Brewer, Terrence L Trentman, Michael G Ivancic, et al.
Headache|August 28, 2020
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% ResponseGregor Broessner, Uwe Reuter, Jo H Bonner, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialHong Sun, David W Dodick, Stephen Silberstein, et al.
The Journal of Pain|December 3, 2014
Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an exampleDavid W Dodick, Catherine C Turkel, Ronald E DeGryse, et al.
Pageof 37